Portal de Periódicos da CAPES

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

2021; Elsevier BV; Volume: 2; Issue: 6 Linguagem: Inglês

10.1016/j.medj.2021.04.003

2666-6359

Shirin Kalimuddin, C Tham, Martin Qui, Ruklanthi de Alwis, Jean Xiang Ying Sim, Joey Ming Er Lim, Hwee-Cheng Tan, Ayesa Syenina, Summer L. Zhang, Nina Le Bert, Anthony T. Tan, Yan Shan Leong, Jia Xin Yee, Eugenia Z. Ong, Eng Eong Ooi, Antonio Bertoletti, Jenny G. Low,

Immunotherapy and Immune Responses

RNA vaccines against coronavirus disease 2019 (COVID-19) have demonstrated ∼95% efficacy in phase III clinical trials. Although complete vaccination consisted of 2 doses, the onset of protection for both licensed RNA vaccines was observed as early as 12 days after a single dose. The adaptive immune response that coincides with this onset of protection could represent the necessary elements of immunity against COVID-19.